168 related articles for article (PubMed ID: 35850524)
21. Identification of the Novel Tumor Suppressor Role of FOCAD/miR-491-5p to Inhibit Cancer Stemness, Drug Resistance and Metastasis via Regulating RABIF/MMP Signaling in Triple Negative Breast Cancer.
Huang WC; Chi HC; Tung SL; Chen PM; Shih YC; Huang YC; Chu PY
Cells; 2021 Sep; 10(10):. PubMed ID: 34685504
[TBL] [Abstract][Full Text] [Related]
22. miR-17-5p suppresses cell proliferation and invasion by targeting ETV1 in triple-negative breast cancer.
Li J; Lai Y; Ma J; Liu Y; Bi J; Zhang L; Chen L; Yao C; Lv W; Chang G; Wang S; Ouyang M; Wang W
BMC Cancer; 2017 Nov; 17(1):745. PubMed ID: 29126392
[TBL] [Abstract][Full Text] [Related]
23. MicroRNA-455-3p promotes invasion and migration in triple negative breast cancer by targeting tumor suppressor EI24.
Li Z; Meng Q; Pan A; Wu X; Cui J; Wang Y; Li L
Oncotarget; 2017 Mar; 8(12):19455-19466. PubMed ID: 28038450
[TBL] [Abstract][Full Text] [Related]
24. MicroRNA-101 inhibits cell progression and increases paclitaxel sensitivity by suppressing MCL-1 expression in human triple-negative breast cancer.
Liu X; Tang H; Chen J; Song C; Yang L; Liu P; Wang N; Xie X; Lin X; Xie X
Oncotarget; 2015 Aug; 6(24):20070-83. PubMed ID: 26036638
[TBL] [Abstract][Full Text] [Related]
25. BRCA mutations cause reduction in miR-200c expression in triple negative breast cancer.
Erturk E; Cecener G; Tezcan G; Egeli U; Tunca B; Gokgoz S; Tolunay S; Tasdelen I
Gene; 2015 Feb; 556(2):163-9. PubMed ID: 25445393
[TBL] [Abstract][Full Text] [Related]
26. Curcumol enhances the sensitivity of doxorubicin in triple-negative breast cancer via regulating the miR-181b-2-3p-ABCC3 axis.
Zeng C; Fan D; Xu Y; Li X; Yuan J; Yang Q; Zhou X; Lu J; Zhang C; Han J; Gu J; Gao Y; Sun L; Wang S
Biochem Pharmacol; 2020 Apr; 174():113795. PubMed ID: 31926937
[TBL] [Abstract][Full Text] [Related]
27. Identification of miR-3182 and miR-3143 target genes involved in the cell cycle as a novel approach in TNBC treatment: A systems biology approach.
Khazaei-Poul Y; Mirmotalebisohi SA; Zali H; Molavi Z; Mohammadi-Yeganeh S
Chem Biol Drug Des; 2023 Mar; 101(3):662-677. PubMed ID: 36310371
[TBL] [Abstract][Full Text] [Related]
28. A Novel Bioengineered miR-127 Prodrug Suppresses the Growth and Metastatic Potential of Triple-Negative Breast Cancer Cells.
Umeh-Garcia M; Simion C; Ho PY; Batra N; Berg AL; Carraway KL; Yu A; Sweeney C
Cancer Res; 2020 Feb; 80(3):418-429. PubMed ID: 31694904
[TBL] [Abstract][Full Text] [Related]
29. Dual Suppressive Effect of miR-34a on the FOXM1/eEF2-Kinase Axis Regulates Triple-Negative Breast Cancer Growth and Invasion.
Bayraktar R; Ivan C; Bayraktar E; Kanlikilicer P; Kabil NN; Kahraman N; Mokhlis HA; Karakas D; Rodriguez-Aguayo C; Arslan A; Sheng J; Wong S; Lopez-Berestein G; Calin GA; Ozpolat B
Clin Cancer Res; 2018 Sep; 24(17):4225-4241. PubMed ID: 29748184
[No Abstract] [Full Text] [Related]
30. Tetraarsenic hexoxide enhances generation of mitochondrial ROS to promote pyroptosis by inducing the activation of caspase-3/GSDME in triple-negative breast cancer cells.
An H; Heo JS; Kim P; Lian Z; Lee S; Park J; Hong E; Pang K; Park Y; Ooshima A; Lee J; Son M; Park H; Wu Z; Park KS; Kim SJ; Bae I; Yang KM
Cell Death Dis; 2021 Feb; 12(2):159. PubMed ID: 33558527
[TBL] [Abstract][Full Text] [Related]
31. MicroRNA-200b targets protein kinase Cα and suppresses triple-negative breast cancer metastasis.
Humphries B; Wang Z; Oom AL; Fisher T; Tan D; Cui Y; Jiang Y; Yang C
Carcinogenesis; 2014 Oct; 35(10):2254-63. PubMed ID: 24925028
[TBL] [Abstract][Full Text] [Related]
32. MicroRNA-200c Inhibits the Metastasis of Triple-Negative Breast Cancer by Targeting ZEB2, an Epithelial-Mesenchymal Transition Regulator.
Chen H; Li Z; Zhang L; Zhang L; Zhang Y; Wang Y; Xu M; Zhong Q
Ann Clin Lab Sci; 2020 Jul; 50(4):519-527. PubMed ID: 32826250
[TBL] [Abstract][Full Text] [Related]
33. Isodeoxyelephantopin, a Sesquiterpene Lactone Induces ROS Generation, Suppresses NF-κB Activation, Modulates LncRNA Expression and Exhibit Activities Against Breast Cancer.
Verma SS; Rai V; Awasthee N; Dhasmana A; Rajalaksmi DS; Nair MS; Gupta SC
Sci Rep; 2019 Nov; 9(1):17980. PubMed ID: 31784542
[TBL] [Abstract][Full Text] [Related]
34. MiR-92b inhibited cells EMT by targeting Gabra3 and predicted prognosis of triple negative breast cancer patients.
Li YY; Zheng XH; Deng AP; Wang Y; Liu J; Zhou Q; Cheng GY; Jiang Q
Eur Rev Med Pharmacol Sci; 2019 Dec; 23(23):10433-10442. PubMed ID: 31841197
[TBL] [Abstract][Full Text] [Related]
35. LncRNA LUCAT1 facilitates tumorigenesis and metastasis of triple-negative breast cancer through modulating miR-5702.
Mou E; Wang H
Biosci Rep; 2019 Sep; 39(9):. PubMed ID: 31399501
[TBL] [Abstract][Full Text] [Related]
36. MicroRNA-17 acts as a tumor chemosensitizer by targeting JAB1/CSN5 in triple-negative breast cancer.
Wang S; Oh DY; Leventaki V; Drakos E; Zhang R; Sahin AA; Resetkova E; Edgerton ME; Wu W; Claret FX
Cancer Lett; 2019 Nov; 465():12-23. PubMed ID: 31473252
[TBL] [Abstract][Full Text] [Related]
37. MicroRNA deregulation in triple negative breast cancer reveals a role of miR-498 in regulating BRCA1 expression.
Matamala N; Vargas MT; González-Cámpora R; Arias JI; Menéndez P; Andrés-León E; Yanowsky K; Llaneza-Folgueras A; Miñambres R; Martínez-Delgado B; Benítez J
Oncotarget; 2016 Apr; 7(15):20068-79. PubMed ID: 26933805
[TBL] [Abstract][Full Text] [Related]
38. LncRNA WEE2-AS1 promotes proliferation and inhibits apoptosis in triple negative breast cancer cells via regulating miR-32-5p/TOB1 axis.
Wang R; Huang Z; Qian C; Wang M; Zheng Y; Jiang R; Yu C
Biochem Biophys Res Commun; 2020 Jun; 526(4):1005-1012. PubMed ID: 32307083
[TBL] [Abstract][Full Text] [Related]
39. MicroRNA-1246 suppresses the metastasis of breast cancer cells by targeting the DYRK1A/PGRN axis to prevent the epithelial-mesenchymal transition.
Wang P; Chen W; Zhang Y; Zhong Q; Li Z; Wang Y
Mol Biol Rep; 2022 Apr; 49(4):2711-2721. PubMed ID: 35059968
[TBL] [Abstract][Full Text] [Related]
40. MicroRNA-301b promotes cell proliferation and apoptosis resistance in triple-negative breast cancer by targeting CYLD.
Song H; Li D; Wu T; Xie D; Hua K; Hu J; Deng X; Ji C; Deng Y; Fang L
BMB Rep; 2018 Nov; 51(11):602-607. PubMed ID: 30269739
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]